Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHalma Regulatory News (HLMA)

Share Price Information for Halma (HLMA)

Share Price is delayed by 15 minutes
Get Live Data
4,664.00    -214.00 (-4.39%)
Bid:
4,682.00
Ask:
4,686.00
Spread: 4.00 (0.085%)
Market Cap: £17.62b
HLMA Live PriceLast checked at - London Stock Exchange

Intraday Halma Share Chart

Acquisitions

25 Oct 2023 07:00

RNS Number : 1552R
Halma PLC
25 October 2023
 

Halma plc ('Halma' or the 'Group')

Acquisitions

Halma, the global group of life-saving technology companies, today announces that it has completed two bolt-on acquisitions for an aggregate maximum total consideration of approximately £46.5m.

 

In the Environmental and Analysis sector, Halma company, Alicat Scientific, Inc. (Alicat), has acquired the Alpha Instrumatics Group (Alpha Instrumatics).

 

Based in Bradford, UK, Alpha Instrumatics designs and manufactures devices for high-precision measurement of trace moisture found in gases. Trace moisture analysis allows the safer operation of industrial equipment, more efficient transfer of hydrocarbons, and more accurate detection of pollutants. Alpha Instrumatics' devices are used in growth markets, including the industrial gas and aerospace markets, as well as industries aligned to the new energy transition. This acquisition extends Alicat's product offering in its existing and adjacent end markets.

 

The initial cash consideration for Alpha Instrumatics is £31m, on a cash- and debt-free basis, which will be funded from Halma's existing facilities. Additional earn-out considerations are payable in cash, based on its performance over each of the two financial years to 31 March 2025, up to an aggregate maximum of £5.5m. Alpha Instrumatics' consolidated unaudited revenue for the 12 months to 30 September 2023 was £7.8m, with Return on Sales substantially above the upper end of Halma's target range of 18-22%.

 

In the Healthcare sector, Halma company, IZI Medical Products LLC (IZI), has acquired AprioMed AB (AprioMed). AprioMed designs, manufactures and distributes medical devices used for bone biopsies. This acquisition expands IZI's offerings for minimally invasive procedures, complementing its products used to diagnose and treat cancer.

 

The consideration for AprioMed is SEK130m (approximately £10m) on a cash- and debt-free basis, which is funded from Halma's existing facilities. AprioMed's unaudited revenue for the 12 months to 31 March 2023 was SEK40.0 (approximately £3.0m), with Return on Sales above Halma's target range of 18-22%.

Marc Ronchetti, Group Chief Executive of Halma, commented:

 

"Our companies have access to Halma expertise and capital to support their growth locally and internationally. These bolt-on acquisitions are strongly aligned with our purpose and financial model and will bring complementary capabilities to Alicat and IZI Medical, including new technologies and broader market reach. We are excited by the opportunities we see for new standalone companies to join Halma and for our existing companies to add new capabilities through bolt-on acquisitions to grow their businesses over the long term."

 

For further information, please contact:

Halma plc

Marc Ronchetti, Group Chief Executive +44 (0)1494 721111

Steve Gunning, Group Chief Financial Officer

Charles King, Head of Investor Relations +44 (0) 7776 685948

Clayton Hirst, Director of Corporate Affairs +44 (0) 7384 796 013

MHP

Oliver Hughes / Rachel Farrington / Ollie Hoare +44 (0)20 3128 8100 

A copy of this announcement, together with other information about Halma, is available at www.halma.com.

About Halma

Halma is a global group of life-saving technology companies, focused on growing a safer, cleaner, healthier future for everyone, every day. Its purpose defines the three broad markets it operates in:

· Safety - Protecting people's safety and the environment as populations grow, and enhancing worker safety.

· Environment - Addressing the impacts of climate change, pollution and waste, protecting life-critical resources and supporting scientific research.

· Health - Meeting the increasing demand for better healthcare as chronic illness rises, driven by growing and ageing populations and lifestyle changes.

It employs over 8,000 people in more than 20 countries, with major operations in the UK, Mainland Europe, the USA and Asia Pacific. Halma is listed on the London Stock Exchange (LON: HLMA) and is a constituent of the FTSE 100 index.

Halma has been named as one of Britain's Most Admired Companies for the past five years.

For more information www.halma.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQUSSVROWURUAA
Date   Source Headline
21st Jun 20072:17 pmRNSDirector/PDMR Shareholding
19th Jun 20077:01 amRNSFinal Results
13th Jun 20072:41 pmRNSHolding(s) in Company
8th Jun 200710:25 amRNSHolding(s) in Company
4th Jun 200710:48 amRNSHolding(s) in Company
4th Jun 200710:15 amRNSNotice of Board Meeting
4th Jun 200710:08 amRNSTotal Voting Rights
30th Apr 20075:13 pmRNSTotal Voting Rights
26th Apr 20077:01 amRNSTrading Statement
30th Mar 200712:48 pmRNSTotal Voting Rights
29th Mar 20075:33 pmRNSTreasury Stock
23rd Mar 200711:16 amRNSHolding(s) in Company
23rd Mar 200710:34 amRNSDirectorate Change
6th Mar 20072:56 pmRNSHolding(s) in Company
6th Mar 200712:43 pmRNSBlocklisting Interim Review
5th Mar 200710:47 amRNSDirector/PDMR Shareholding
27th Feb 20073:40 pmRNSHolding(s) in Company
22nd Feb 20075:47 pmRNSHolding(s) in Company
19th Feb 20072:37 pmRNSDirector/PDMR Shareholding
8th Feb 200710:56 amRNSAcquisition
6th Feb 20073:39 pmRNSHolding(s) in Company
6th Feb 20079:30 amRNSInvestor Visit
1st Feb 20074:21 pmRNSHolding(s) in Company
16th Jan 20072:52 pmRNSTotal Voting Rights
16th Jan 20072:39 pmRNSHolding(s) in Company
18th Dec 20069:34 amRNSTotal Voting Rights
12th Dec 20063:43 pmRNSTreasury Stock
12th Dec 20063:38 pmRNSDirector/PDMR Shareholding
5th Dec 200610:51 amRNSDoc re. Interim Report 2006
5th Dec 20067:00 amRNSInterim Results
27th Nov 20068:55 amRNSAcquisition
20th Nov 20062:24 pmRNSNotice of Results
9th Nov 20064:43 pmRNSHolding(s) in Company
8th Nov 200612:31 pmRNSHolding(s) in Company
31st Oct 20063:30 pmRNSHolding(s) in Company
26th Oct 20067:00 amRNSTrading Statement
18th Oct 200611:22 amRNSHolding(s) in Company
2nd Oct 20062:07 pmRNSDirector/PDMR Shareholding
15th Sep 20063:08 pmRNSShare Plan Treasury Shares
14th Sep 200610:34 amRNSDirector/PDMR Shareholding
11th Aug 20062:59 pmRNSBlocklisting Interim Review
4th Aug 200612:44 pmRNSHolding(s) in Company
4th Aug 200612:37 pmRNSDoc re. AGM 2006 resolutions
2nd Aug 20067:00 amRNSAGM Statement
1st Aug 20064:20 pmRNSHolding(s) in Company
31st Jul 20065:23 pmRNSHolding(s) in Company
25th Jul 20065:31 pmRNSHolding(s) in Company
25th Jul 20061:15 pmRNSAnnual Information Update
18th Jul 20065:38 pmRNSHolding(s) in Company
10th Jul 20063:10 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.